Scisparc Ltd
SPRC0.684USD
+0.072+11.75%
收盘 02/06, 16:00（美东）报价延迟15分钟
365.67K总市值
亏损市盈率 TTM
关于 Scisparc Ltd 公司
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Scisparc Ltd简介
公司代码SPRC
公司名称Scisparc Ltd
上市日期Dec 22, 2021
CEOWeiss (Amitay)
员工数量2
证券类型Ordinary Share
年结日Dec 22
公司地址20 Raul Wallenberg Street, Tower A
城市TEL AVIV-YAFO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Israel
邮编6971916
电话97236103100
网址https://scisparc.com/
公司代码SPRC
上市日期Dec 22, 2021
CEOWeiss (Amitay)
Scisparc Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Itschak Shrem
Mr. Itschak Shrem
Chairman of the Board
Chairman of the Board
16.00
+9.00%
Mr. Amitay Weiss
Mr. Amitay Weiss
Chief Executive Officer, Director
Chief Executive Officer, Director
1.00
--
Dr. Adi Zuloff-Shani
Dr. Adi Zuloff-Shani
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Oz Adler, CPA
Mr. Oz Adler, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Prof. Ari Shamiss, M.D.
Prof. Ari Shamiss, M.D.
Independent Director
Independent Director
--
--
Mr. Moshe Revach
Mr. Moshe Revach
Director
Director
--
--
Mr. Lior Vider
Mr. Lior Vider
Independent Director
Independent Director
--
--
Ms. Liat Sidi
Ms. Liat Sidi
Director
Director
--
--
Mr. Amnon Shay
Mr. Amnon Shay
Independent Director
Independent Director
--
--
Mr. Alon Dayan
Mr. Alon Dayan
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Itschak Shrem
Mr. Itschak Shrem
Chairman of the Board
Chairman of the Board
16.00
+9.00%
Mr. Amitay Weiss
Mr. Amitay Weiss
Chief Executive Officer, Director
Chief Executive Officer, Director
1.00
--
Dr. Adi Zuloff-Shani
Dr. Adi Zuloff-Shani
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Oz Adler, CPA
Mr. Oz Adler, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Prof. Ari Shamiss, M.D.
Prof. Ari Shamiss, M.D.
Independent Director
Independent Director
--
--
Mr. Moshe Revach
Mr. Moshe Revach
Director
Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 2月1日 周日
更新时间: 2月1日 周日
持股股东
股东类型
持股股东
持股股东
占比
L.I.A. Pure Capital Ltd
10.01%
Ronen (Fatal)
6.60%
Eli (Zamir)
6.60%
Daniel (Nissim)
6.60%
UBS Financial Services, Inc.
0.58%
其他
69.60%
持股股东
持股股东
占比
L.I.A. Pure Capital Ltd
10.01%
Ronen (Fatal)
6.60%
Eli (Zamir)
6.60%
Daniel (Nissim)
6.60%
UBS Financial Services, Inc.
0.58%
其他
69.60%
股东类型
持股股东
占比
Individual Investor
19.81%
Corporation
10.01%
Investment Advisor
0.58%
Research Firm
0.03%
Bank and Trust
0.01%
其他
69.56%
机构持股
更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
14
27.07K
0.62%
+11.94K
2025Q3
15
9.03K
0.56%
+2.09K
2025Q2
20
5.89K
1.10%
-4.32K
2025Q1
22
123.94K
1.13%
-90.52K
2024Q4
22
186.52K
1.22%
-6.68K
2024Q3
20
179.36K
1.73%
+90.02K
2024Q2
22
138.03K
12.19%
+104.31K
2024Q1
20
67.89K
2.29%
+37.60K
2023Q4
19
11.96K
4.65%
-10.95K
2023Q3
23
5.71K
4.48%
-17.08K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Ronen (Fatal)
287.27K
8.73%
+287.27K
--
Nov 28, 2025
Eli (Zamir)
287.27K
8.73%
+287.27K
--
Nov 28, 2025
Daniel (Nissim)
287.27K
8.73%
+287.27K
--
Nov 28, 2025
UBS Financial Services, Inc.
8.00
0%
-3.30K
-99.76%
Sep 30, 2025
BofA Global Research (US)
1.37K
0.04%
+1.36K
+68200.00%
Sep 30, 2025
UBS Switzerland AG
5.40K
0.16%
+5.40K
--
Sep 30, 2025
Shrem (Itschak)
16.00
0%
+9.00
+128.57%
Apr 23, 2025
SBI Securities Co., Ltd.
12.00
0%
-6.00
-33.33%
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
--
0%
-1.00
-100.00%
Sep 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
May 21, 2025
Merger
21→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
公告日期
除权除息日
类型
比率
May 21, 2025
Merger
21→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
Sep 20, 2023
Merger
26→1
